Pfizer Could Be Gearing Up For Major Purchases Reports VFC's Stock House
(EMAILWIRE.COM, April 23, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, believes that recent moves to sell off non-core assets by Pfizer may be an indication that company will look to replenish its pipeline by making some major purchases.
It has been mentioned, however, that Pfizer will initiate some share buybacks and utilize the new found spare cash to boost investor value in other ways, but it's also fair to speculate that the pharmaceutical powerhouse might look to complete a key acquisition or two - and the season for such a move is ripe.
With Pfizer's significant cash infusion, it wouldn't surprise anyone to see the company join the ranks of acquiring companies on the move. PFE already has relationships with a few smaller, developing companies - such as Lpath Inc. (LPTN) - that would make for nice, cheap acquisitions to start pumping the pipeline full of technology and new product candidates, but it would also be expected to see a move towards closer-to-market candidates and/or companies who might already have a product on the market, although still in the early stages of full commercialization.
Synergy Pharmaceuticals (SGYP) is another example of an earlier-stage company that could be had for a relative fraction of its market potential right now. Boasting only a market cap of just over two hundred million, this company's main product - Plecanatide - is more than halfway through a Phase II/III trial that - if successful - would position the product to be approved in the multi-billion dollar chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C) markets.
Regardless of the strategy that Pfizer undertakes to replenish its pipeline, I think it's safe to say that Pfizer's plan to sell off its business assets not related to the core drug unit could have as much to do with preparations to enter the buyer's market as it does to carry out the share buybacks discussed in recent news articles.
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCs Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
The goal of VFC's Stock House is to bring new ideas, companies and discussions to investors and readers. With respect to the increased amount of time necessary to maintain quality, VFC's Stock House is at times compensated from third parties to research and cover certain companies that fit the profile of what interests the readers of VFC's Stock House. While taking compensation poses as an inherent perception of bias in coverage, the ultimate goal is to bring ideas and information to the eyes of readers, who can then decide what is and what is not relevant.